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Abstract
Background: Endpoints that are commonly used in trials of moderate/severe stroke may be less frequent in patients
with minor, non-disabling stroke thus inflating sample sizes. We tested whether trial efficiency might be improved with
composite endpoints.
Methods: We prospectively recruited patients with lacunar and minor non-lacunar ischaemic stroke (NIHSS 7) and
assessed recurrent vascular events (stroke, transient ischaemic attack (TIA), ischemic heart disease (IHD)), modified
Rankin Score (mRS) and cognitive testing with the Addenbrooke’s Cognitive Examination (ACE-R) one year post-stroke.
For a potential secondary prevention randomised controlled trial (RCT), we estimated sample sizes using individual or
combined outcomes, at power 80% (and 90%), alpha 5%, required to detect a relative 10% risk reduction.
Results: Amongst 264 patients (118 lacunar, 146 non-lacunar), at one year, 30/264 (11%) patients had a recurrent
vascular event, 5 (2%) had died, 3 (1%) had clinically-diagnosed dementia, 53/264 (20%) had mRS 3 and 29/158
(19%) had ACE-R 82 (57 could not attend for cognitive testing). For a potential trial, at 80% power, using mRS 3
alone would require n> 5000 participants, recurrent vascular events alone n¼ 9908 participants, and a composite
of any recurrent vascular event, ACE-R 82, dementia or mRS 2 (present in 56% of patients) n¼ 2224 patients.
However, including cognition increased missing data. Results were similar for lacunar and non-lacunar minor
ischaemic stroke.
Conclusions: Composite outcomes including vascular events, dependency, and cognition reduce sample size and
increase efficiency, feasibility, and relevance to patients of RCTs in minor ischaemic stroke. Efficiency might be improved
further with more practical cognitive test strategies.
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Introduction
The endpoints commonly used in trials of treatments
for moderate and severe stroke,1 such as death or
dependency (often measured on the modified Rankin
Scale (mRS)),2 may occur less frequently in patients
with minor stroke and, therefore, inflate the sample
size required in a randomised controlled trial (RCT).
Such trials might include testing treatments for lacunar
stroke, an important but neglected subtype of ischaemic
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stroke for which currently there is no specific treatment,
but where trials are planned.3
Although death or dependence2 is important, other
individual outcomes may also be of concern to patients
with minor stroke, such as cognitive decline.
Combining outcome measures into a composite out-
come has the potential to increase trial efficiency by
increasing the proportion of patients with the endpoint,
improving power at smaller sample sizes and reducing
costs and trial duration. Combined outcomes may also
provide an overall outcome which captures several fac-
tors of relevance to patients.
We used data from a longitudinal observational
study of patients with a lacunar or minor non-lacunar
ischaemic stroke to test the effect of several possible
single and composite outcomes, assessed at one year
after index stroke, on sample size estimates for RCTs.
Methods
We recruited consecutive inpatients and outpatients
who presented to our Regional Stroke Service with a
lacunar or minor non-lacunar ischaemic stroke.
‘Minor’ stroke was defined as NIHSS 7 and expected
to be non-disabling at the point of assessment, i.e.
recovery to no disability in basic activities of daily
living (ADLs)4 like washing, dressing walking, bathing,
but which might cause some reduction in instrumental
ADLs.5 We recorded patient characteristics and med-
ical history including vascular risk factors at recruit-
ment, as reported previously.5
The study was approved by Lothian Research Ethics
committee (REC 09/81,101/54) and NHS Lothian
RþD Office (2009/W/NEU/14), and all patients gave
written informed consent.
We introduced cognitive testing with the
Addenbrooke’s cognitive examination-revised version
(ACE-R)6 at one month and one year after stroke; cog-
nitive testing did not start until after the first 56 patients
had been recruited due to delays in obtaining ethics
approval. We considered a score of 82 to indicate cog-
nitive impairment as it was the cut-off recommended in a
validation paper as having a high specificity for demen-
tia.6 The ACE-R is a multi-domain cognitive screening
tool, similar to the Montreal Cognitive Assessment
(MoCA) in many respects including its sensitivity and
specificity for dementia and multi-domain cognitive
impairment in the post-stroke setting.7
We followed-up all patients face-to-face at one year
post-stroke to identify any history suggestive of recur-
rent stroke, TIA, ischaemic heart disease (IHD)
whether new episode of angina, or myocardial infarc-
tion during follow-up, performed physical examination
including NIHSS and blood pressure, and measured the
modified Rankin scale (mRS) using the structured
method.8 If patients were unable to attend we
performed telephone assessment, and if that was impos-
sible we obtained relevant information from carers or
the family doctor.
Statistical analysis
We used R statistical software (R Foundation for
Statistical Computing, Vienna, Austria, http://www.
R-project.org/) to run Fisher’s exact test (dichotomous
variables) and the Mann–Whitney U test (continuous
non-parametric variables) in univariate analyses to
compare the characteristics in patients with lacunar
and non-lacunar stroke.
We calculated the sample size required to detect a
10% relative risk reduction in the outcome of interest,
at 80% and 90% power, these effect sizes being similar
to that of several commonly used medical interventions,
e.g. antiplatelets for secondary stroke prevention.9
For example, if an outcome occurred in 40% of
participants, we calculated the sample size required to
detect a reduction of 4%, from 40% to 36%. If an
outcome occurred in 5% of participants, we calculated
the sample required to detect a reduction of 0.5%, from
5% to 4.5%.
We performed all sample size calculations for
powers of 80% and 90%, as these are two conventional
values.10 We calculated the sample size for lacunar and
non-lacunar stroke separately, and then for all stroke
combined.
We first tested single outcomes, e.g. ‘recurrent
stroke’ or, ‘ACE-R 82,’ and then tested combinations
of vascular events, e.g. ‘recurrent stroke or TIA.’ We
then incorporated dependence into the outcomes
(testing both mRS 2 and mRS 3), and finally we
incorporated cognition e.g. ‘Stroke, TIA, IHD, ACE-
R 82, dementia, death or mRS 2.’ We then tested
outcomes that included cognition, dependency and
death but not recurrent vascular events, e.g. ‘ACE-
R 82, dementia, death or mRS 3’ to allow for
RCTs of differing objectives and agents. We included
dementia as well as ACE-R 82 since dementia, a clin-
ical diagnosis, might be available in a patient who was
not able to undergo trial-based cognitive test like the
ACE-R. A composite endpoint is a binary outcome
measure: it is considered to have occurred if a patient
had one or more of the component endpoints: for
example if a patient had either a recurrent stroke, or
a TIA, or both a stroke and TIA we would consider
that they had experienced the endpoint ‘Stroke or TIA.’
Results
We screened 471 patients with a potential diagnosis
of minor ischaemic stroke and recruited 264
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(details, Figure 1).5 About 208 patients had cognitive
testing at baseline since cognitive testing was intro-
duced after the first 56 patients were recruited.
Patient characteristics and rates
of individual outcomes
At baseline (Table 1) the median age was 67 (range
36–98), 110/264 (42%) were female, the median
NIHSS was 2 (interquartile range, IQR 1–3) and 118/
264 (45%) patients had a lacunar stroke. The median
mRS at the time of initial cognitive assessment was 1
(IQR 0-2).
At one year, we followed up all 264 patients to ascer-
tain if they were alive or dead, had had a recurrent
vascular event, and their functional status; patients
seen in person underwent repeat cognitive assessment.
We assessed 204 in person, 47 by telephone, five via
carers or relatives, and eight via their GP (Figure 1).
At one year, 30 (11%) patients had had a recurrent
stroke or TIA, 5 (2%) had died, and 3 (1%) had been
diagnosed clinically with dementia. Many patients
118/264 (45%) still had some symptoms of stroke and
53/264 (20%) required assistance from family or carers
with activities of daily living at least once per week.
More patients with non-lacunar stroke had new
diagnosis of peripheral vascular disease during follow-
up(10/146 patients with non-lacunar stroke v 0/118
patients with lacunar stroke), there were no other
statistically significant differences in outcomes between
patients with lacunar or non-lacunar stroke.
Of the 208 patients recruited after cognitive testing
was introduced, 151/208 were tested at one year of
whom 29/151 (19%) had an ACE-R 82. Of the
57/208 patients not having one year cognitive testing,
3 had died, 32 declined further testing, 19 were too
unwell, and 3 had visual or language disabilities
precluding testing.
Sample size estimations
The effect of several single and composite endpoints
on sample size, at 80% and 90% power, is shown in
Table 2. For example, 10% of patients had a recurrent
stroke (26/264), so to detect a 10% relative reduction in
recurrent stroke at one year (from 26/264 to 23/264)
would require 29,818 patients at 80% power. A larger
proportion of patients, 29/151, 19% of those cogni-
tively tested, had an ACE-R 82 at one year, which
would require a sample size of 12,570 to detect a 10%
reduction. However, 118/264 (45%) of patients had a
mRS 2, therefore a sample size of 3864 would
be required to detect a 10% reduction in mRS 2.
The sample size estimations were similar for patients
with lacunar and non-lacunar stroke since the propor-
tion of most outcomes (Table 1) was similar in these
two stroke subtypes (supplementary information).
For composite outcomes at one year, such as ‘recur-
rent stroke or TIA, new IHD, or death,’ 25% would
have the outcome, requiring a sample size of 9144 to
be followed up to one year at 80% power (Table 2;
12,240 patients at 90% power, Supplementary Table 1).
Figure 1. Recruitment and follow-up.
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Table 1. Characteristics of patients at baseline and at one year.
Lacunar
n¼ 118
Non-lacunar
n¼ 146 p
All ischaemic
stroke
Median age years (IQR) 64(55–65) 69(61–77) 0.0063 67(59–67)
Female gender (%) 51(43%) 59(41%) 0.71 110(42%)
Previous TIA 11(9%) 17(12%) 0.68 28(11%)
Previous stroke 16(14%) 16(11%) 0.57 32(12%)
Ischaemic heart disease (IHD) 19(16%) 34(23%) 0.17 53(20%)
Diagnosis of peripheral vascular disease (PVD) 3(3%) 12(8%) 0.032 15(6%)
Diabetes 12(10%) 18(12%) 0.70 30(11%)
Hypertension 81(69%) 106(72%) 0.50 187(71%)
Atrial fibrillation (AF) 7(6%) 18(12%) 0.09 25(9%)
Diagnosis of hyperlipidaemia prior to
index stroke, or at presentation
73(62%) 88(60%) 0.80 161(62%)
Current smoker 46(39%) 44(30%) 0.15 90(34%)
Median NIHSS (IQR) 2(2–4) 2(1–3) 0.0092 2(1–3)
Median systolic BP (IQR) 147(130–158.5) 138(125.5–159) 0.16 142.5(130–159)
Median mRS (IQR) at baseline assessment 1(1–2) 1(1–2) 0.67 1(1–2)
Characteristics at 1 year
Diagnosis of dementia 1(1%) 2(1%) 1.00 3(1%)
IHD in the year following the stroke
(e.g. ongoing angina, or new myocardial infarction)
14(12%) 22(15%) 0.48 36(14%)
NIHSS at 1 year (IQR) 0(0–1) 0(0–0) 0.72 0(0–0.25)
NIHSS at 1 year 1 23(26%) 27(24%) 0.75 50(19%)
mRS (IQR) 1(0–2) 1(1–2) 0.12 1(1–2)
mRS¼ 0 (No symptoms) 30(21%) 32(27%) 0.24 62(23%)
mRS 1 (Some symptoms) 86(73%) 116(79%) 0.24 202(77%)
mRS 2 47(40%) 71(49%) 0.17 118(45%)
mRS 3 20(17%) 33(23%) 0.28 53(20%)
New TIA 3(3%) 4(3%) 1 7(3%)
New stroke 10(8%) 15(10%) 0.68 25(9%)
Either new stroke or TIA 12(10%) 18(12%) 0.70 30(11%)
ACE-R at 1 year median (Interquartile range)
in n¼ 151 tested at 1 year
92(71–96) 90(59–94) 0.54 91(59–95)
ACE-R 82 in n¼ 151 tested at 1 year 14(22%) 15(17%) 0.53 29(19%)
Bold¼ p values that indicate significant differences at p< 0.01 between lacunar and cortical stroke subgroups.
Table 2. Estimated sample size required to detect a 10% reduction in event rate for various combined outcomes
at 80% power. Full details of individual and different combinations of outcomes at 80% and 90% power for lacunar
and non-lacunar stroke at two mRS cut points are given in Supplementary Table 1.
Sample size
required
Sample size if
combined with
mRS 3
Sample size if
combined with
mRS 2 AND ACE 82a
Recurrent stroke or TIA 23,600 7958 3090
Recurrent stroke or TIA or IHD 9908 4398 2224
Recurrent stroke, TIA, IHD, death
Similar to the major adverse
cardiovascular events (MACE)
endpoint used in cardiovascular trials.
9144 4398 2224
aIncludes clinical diagnosis of dementia.
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At 80% power, adding mRS 3 to this composite
reduced the sample size to approximately half (4398)
and replacing mRS 3 with mRS 2 reduced the
sample size to approximately a third (3126) of 9144.
Then, adding ACE-R 82 to the composite outcome
of ‘stroke, TIA, new IHD, dementia diagnosis, death
or an mRS 2,’ which occurred in 56% of patients
without any double counting, reduced the sample size
to 2224 patients.
Although including ACE-R in the composite out-
come reduced the sample size, it introduced missing
data: 57/208 (27%) patients recruited with baseline cog-
nitive testing could not have cognitive testing at one
year mainly for medical reasons. There were fewer miss-
ing outcomes when considered as part of a composite
endpoint: although 27% of patients had a missing out-
come for ‘ACE-R 82,’ only 11% had missing data for
‘stroke, TIA, IHD, ACE-R 82, dementia, death or
mRS 2.’ Figure 2 illustrates that while composite end-
points that include ACE-R do help to reduce sample
size, up to 30% of the cognitive data may be missing,
whereas composites that do not include cognition have
very little missing data but need larger sample sizes.
One way to compensate for missing data is to
increase the sample size recruited (Supplementary
Table 2). If retention progresses in a similar way to
MSS-2 then to detect a 10% reduction in ‘stoke, TIA,
dementia, death, mRS< /¼2 or ACE-R> /¼82,’ 2499
patients would need to be recruited in order for 2106 to
be followed up at one year.
Another method is to use the ‘last observation car-
ried forward’ (LOCF) method. About 157 patients had
cognitive testing at 1–3 months post stroke of which 36
had ACE-R 82. By one year, 19/36 had ACE-R 82,
8 had an ACE-R< 82 and 9 were not tested; in con-
trast, of the 121 patients who had ACE-R< 82 at 1–3
months 4 had an ACE-R 82, at one year and 13 were
not tested. If the LOCF method is used for the missing
cognitive data, then 126/208 patients have the outcome
measure of stroke, TIA, dementia, death, mRS>/¼2 or
ACE-R 82 at one year, with only 9% of patients lost
to follow-up at one year. This suggests that one year
data on 1748 patients would need to be recorded to
detect a 10% reduction in outcome rate, at 80%
power and 1880 would need to be recruited in order
to follow-up 1748 patients at one year.
Discussion
We demonstrate that in patients with minor ischaemic
stroke, in whom some important individual outcome
events are infrequent, that a composite outcome such
as ‘recurrent stroke, TIA, new IHD, ACE-R 82, new
diagnosis of dementia or an mRS 2’ produced an out-
come event rate of 56% and hence could substantially
reduce sample sizes required to detect modest but
worthwhile treatment effects while retaining conven-
tional power. The net effect would be smaller, less
expensive and more rapidly completed RCTs in sub-
types of stroke that are less common therefore provide
a smaller pool from which to recruit, and have been less
studied to date.
Adding mRS 3 halved the sample size from that
based on recurrent stroke/TIA/IHD; using mRS 2
reduced it to a third; and adding in ACE-R 82 reduced
it to an eighth of the starting sample. There was little
difference between samples calculated for lacunar and
non-lacunar stroke because the proportions of outcomes
Figure 2. The effect of adding variables to a combined outcome on overall sample size required to detect a 10% reduction at
80% power.
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in these minor stroke patients were similar. These calcu-
lations were based on patients with similar characteris-
tics to patients currently being recruited to a RCT testing
interventions to prevent progression of small vessel
disease in patients with lacunar stroke (LACI-1,
NCT02481323) and to those who were recruited in the
Secondary Prevention of Small Subcortical Stroke
(SPS3) trial in lacunar stroke.11 However, the data
came from a single population at a single centre that
may limit generalisation to other settings. A similar exer-
cise should be undertaken in other populations since
outcome rates may differ.
Despite these benefits, composite outcomes may also
have drawbacks that should be considered carefully.
Interpretation may be more difficult since analyses
based on composite outcomes generally emphasise the
first event so a minor initial outcome can mask a sub-
sequent major one.12 Additionally, it is theoretically
possible for a treatment to have a positive effect on
one outcome, and a negative effect on another, so a
neutral trial result may mask a clinically significant out-
come. This can be partly mitigated by careful presenta-
tion of results so that both individual and composite
outcomes are easily visible to the reader. It is also
important to choose components that are both relevant
to patients and are biologically plausible (e.g. cognitive
rehabilitation may reduce dependence but not recurrent
stroke).
The combined outcome approach suggested here
assumes that all outcomes are equally significant and
of equal weight. Further data are needed to suggest, for
instance, whether patients consider myocardial infarc-
tion to be as severe as a diagnosis of dementia. Other
approaches, such as weighting the different outcome
measures based on their relevance to patients, could
be tested in future work. Example approaches include
ordinalising recurrent events (as used in the TARDIS
trial13,14), using global tests that integrate individual
outcomes statistically (e.g. using the Wald or Wei–
Lachin tests15,16) or using Pocock’s Win Ratio.17
Including cognitive testing in the outcome of any
stroke RCT introduces attrition bias, as some patients
are unable to have cognitive testing at follow-up for
various reasons, even when a relatively simple screening
tool is used, as here (Figure 2). This leads to missing
data and significant underestimation of post-stroke
cognitive impairment.18 Missing data is a challenge
for any clinical trial; whilst increasing the number of
patients recruited and using the LOCF method can
ensure that the necessary number reach one year
follow-up, both methods may increase bias. Patients
that do return for follow-up are unrepresentative of
those that do not return, and the use of LOCF assumes
that cognition is static from one to three months to one
year post-stroke. How missing data is handled can have
a substantial impact on results, the method used should
be explicit in the protocol and statistical analysis plan,
and not decided post-hoc.19 The SPS3 trial20 managed
to achieve more complete follow-up – with only 11% of
patients having missing cognitive tests at five-year
follow-up. However, they only recruited patients who
were able to have baseline cognitive tests in the sub-
acute phase, and our patients were recruited a median
of four days post-stroke.
Telephone cognitive assessment could reduce attri-
tion bias, although is only applicable to some aspects of
cognition. Several phone tests, at various stages of val-
idation, are available.21 However, these do not allow
for multi-domain screening of visuospatial and certain
aspects of executive function.22 Even with a telephone
assessment of cognition, there would still have been
more missing outcomes than for other endpoints,
underlining the problem of assessing cognition after
stroke. Whilst the sample size could be increased to
account for the expected proportion of patients with
missing outcomes, such a sample may still be biased
towards the healthier patients. Further research is
needed to estimate required sample size if telephone
cognitive testing is used. Self-reported outcome meas-
ures are available for several stroke-related outcomes23
and more are needed.24,25
For a common condition such as a stroke, a rela-
tively small reduction in adverse outcomes would bene-
fit a large number of people and therefore small effect
sizes are worth trying to detect reliably with the smal-
lest sample and shortest duration of follow-up possible,
to reduce trial costs and minimise participant and
researcher trial fatigue. Composite outcomes have the
potential to do this and so accelerate trials of potential
treatments; however, they can be more challenging to
interpret, and care needs to be given when considering
how to handle missing data.
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